Search

Your search keyword '"Bardiès M"' showing total 286 results
Start Over Author "Bardiès M"
286 results on '"Bardiès M"'

7. GATE : a simulation toolkit for PET and SPECT

Author

Jan, S., Santin, G., Strul, D., Staelens, S., Assie, K., Autret, D., Avner, S., Barbier, R., Bardies, M., Bloomfield, P. M., Brasse, D., Breton, V., Bruyndonckx, P., Buvat, I., Chatziioannou, A. F., Choi, Y., Chung, Y. H., Comtat, C., Donnarieix, D., Ferrer, L., Glick, S. J., Groiselle, C. J., Guez, D., Honore, P. -F., Kerhoas-Cavata, S., Kirov, A. S., Kohli, V., Koole, M., Krieguer, M., van der Laan, D. J., Lamare, F., Largeron, G., Lartizien, C., Lazaro, D., Maas, M. C., Maigne, L., Mayet, F., Melot, F., Merheb, C., Pennacchio, E., Perez, J., Pietrzyk, U., Rannou, F. R., Rey, M., Schaart, D. R., Schmidtlein, C. R., Simon, L., Song, T. Y., Vieira, J. -M., Visvikis, D., Van de Walle, R., Wieers, E., and Morel, C.

Subjects
Physics - Medical Physics, Physics - Biological Physics
Abstract

Monte Carlo simulation is an essential tool in emission tomography that can assist in the design of new medical imaging devices, the optimization of acquisition protocols, and the development or assessment of image reconstruction algorithms and correction techniques. GATE, the Geant4 Application for Tomographic Emission, encapsulates the Geant4 libraries to achieve a modular, versatile, scripted simulation toolkit adapted to the field of nuclear medicine. In particular, GATE allows the description of time-dependent phenomena such as source or detector movement, and source decay kinetics. This feature makes it possible to simulate time curves under realistic acquisition conditions and to test dynamic reconstruction algorithms. A public release of GATE licensed under the GNU Lesser General Public License can be downloaded at the address http://www-lphe.epfl.ch/GATE/.

Published
2004
Full Text
View/download PDF

8. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals

Author

Korde, A, Mikolajczak, R, Kolenc, P, Bouziotis, P, Westin, H, Lauritzen, M, Koole, M, Herth, M, Bardiès, M, Martins, A, Paulo, A, Lyashchenko, S, Todde, S, Nag, S, Lamprou, E, Abrunhosa, A, Giammarile, F, Decristoforo, C, Korde A., Mikolajczak R., Kolenc P., Bouziotis P., Westin H., Lauritzen M., Koole M., Herth M. M., Bardiès M., Martins A. F., Paulo A., Lyashchenko S. K., Todde S., Nag S., Lamprou E., Abrunhosa A., Giammarile F., Decristoforo C., Korde, A, Mikolajczak, R, Kolenc, P, Bouziotis, P, Westin, H, Lauritzen, M, Koole, M, Herth, M, Bardiès, M, Martins, A, Paulo, A, Lyashchenko, S, Todde, S, Nag, S, Lamprou, E, Abrunhosa, A, Giammarile, F, Decristoforo, C, Korde A., Mikolajczak R., Kolenc P., Bouziotis P., Westin H., Lauritzen M., Koole M., Herth M. M., Bardiès M., Martins A. F., Paulo A., Lyashchenko S. K., Todde S., Nag S., Lamprou E., Abrunhosa A., Giammarile F., and Decristoforo C.

Abstract

Background: The development of radiopharmaceuticals requires extensive evaluation before they can be applied in a diagnostic or therapeutic setting in Nuclear Medicine. Chemical, radiochemical, and pharmaceutical parameters must be established and verified to ensure the quality of these novel products. Main body: To provide supportive evidence for the expected human in vivo behaviour, particularly related to safety and efficacy, additional tests, often referred to as “non-clinical” or “preclinical” are mandatory. This document is an outcome of a Technical Meeting of the International Atomic Energy Agency. It summarises the considerations necessary for non-clinical studies to accommodate the regulatory requirements for clinical translation of radiopharmaceuticals. These considerations include non-clinical pharmacology, radiation exposure and effects, toxicological studies, pharmacokinetic modelling, and imaging studies. Additionally, standardisation of different specific clinical applications is discussed. Conclusion: This document is intended as a guide for radiopharmaceutical scientists, Nuclear Medicine specialists, and regulatory professionals to bring innovative diagnostic and therapeutic radiopharmaceuticals into the clinical evaluation process in a safe and effective way.

Published
2022

13. Simulating radial dose of ion tracks in liquid water simulated with Geant4-DNA: A comparative study

Author

Incerti, S., Psaltaki, M., Gillet, P., Barberet, Ph., Bardiès, M., Bernal, M.A., Bordage, M.-C., Breton, V., Davidkova, M., Delage, E., El Bitar, Z., Francis, Z., Guatelli, S., Ivanchenko, A., Ivanchenko, V., Karamitros, M., Lee, S.B., Maigne, L., Meylan, S., Murakami, K., Nieminen, P., Payno, H., Perrot, Y., Petrovic, I., Pham, Q.T., Ristic-Fira, A., Santin, G., Sasaki, T., Seznec, H., Shin, J.I., Stepan, V., Tran, H.N., and Villagrasa, C.

Published
2014
Full Text
View/download PDF

31. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy

Author

Chiesa, C. (Carlo), Sjögreen-Gleisner, K. (Katarina), Flux, G. (Glenn), Gear, J., Walrand, S. (Stéphan), Bacher, K., Eberlein, U., Visser, E.P., Chouin, N., Ljungberg, M., Bardiès, M. (Manuel), Lassmann, M. (Michael), Strigari, L. (Lidia), Konijnenberg, M. (Mark), Chiesa, C. (Carlo), Sjögreen-Gleisner, K. (Katarina), Flux, G. (Glenn), Gear, J., Walrand, S. (Stéphan), Bacher, K., Eberlein, U., Visser, E.P., Chouin, N., Ljungberg, M., Bardiès, M. (Manuel), Lassmann, M. (Michael), Strigari, L. (Lidia), and Konijnenberg, M. (Mark)

Published
2017
Full Text
View/download PDF

32. From fixed activities to personalized treatments in radionuclide therapy: lost in translation?

Author

Flux, G. (Glenn), Sjögreen-Gleisner, K. (Katarina), Chiesa, C. (Carlo), Lassmann, M. (Michael), Chouin, N. (N.), Gear, J. (J.), Bardiès, M. (Manuel), Walrand, S. (Stéphan), Bacher, K. (K.), Eberlein, U. (U.), Ljungberg, M. (M.), Strigari, L. (Lidia), Visser, E. (E.), Konijnenberg, M. (Mark), Flux, G. (Glenn), Sjögreen-Gleisner, K. (Katarina), Chiesa, C. (Carlo), Lassmann, M. (Michael), Chouin, N. (N.), Gear, J. (J.), Bardiès, M. (Manuel), Walrand, S. (Stéphan), Bacher, K. (K.), Eberlein, U. (U.), Ljungberg, M. (M.), Strigari, L. (Lidia), Visser, E. (E.), and Konijnenberg, M. (Mark)

Published
2017
Full Text
View/download PDF

33. From fixed activities to personalized treatments in radionuclide therapy: lost in translation?

Author

Flux, G. D., primary, Sjogreen Gleisner, K., additional, Chiesa, C., additional, Lassmann, M., additional, Chouin, N., additional, Gear, J., additional, Bardiès, M., additional, Walrand, S., additional, Bacher, K., additional, Eberlein, U., additional, Ljungberg, M., additional, Strigari, L., additional, Visser, E., additional, and Konijnenberg, M. W., additional

Published
2017
Full Text
View/download PDF

37. Model-based versus specific dosimetry in diagnostic context: Comparison of three dosimetric approaches

Author

Marcatili, S., Villoing, D., Mauxion, T., McParland, B., Bardiès, M., Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Aniline Compounds, education, [SDV.CAN]Life Sciences [q-bio]/Cancer, Middle Aged, Radiation Dosage, Models, Biological, Imaging, Three-Dimensional, Positron-Emission Tomography, Humans, Female, Benzothiazoles, Radiometry, Tomography, X-Ray Computed, Monte Carlo Method, Software, health care economics and organizations, Aged
Abstract

The dosimetric assessment of novel radiotracers represents a legal requirement in most countries. While the techniques for the computation of internal absorbed dose in a therapeutic context have made huge progresses in recent years, in a diagnostic scenario the absorbed dose is usually extracted from model-based lookup tables, most often derived from International Commission on Radiological Protection (ICRP) or Medical Internal Radiation Dose (MIRD) Committee models. The level of approximation introduced by these models may impact the resulting dosimetry. The aim of this work is to establish whether a more refined approach to dosimetry can be implemented in nuclear medicine diagnostics, by analyzing a specific case.The authors calculated absorbed doses to various organs in six healthy volunteers administered with flutemetamol ((18)F) injection. Each patient underwent from 8 to 10 whole body 3D PET/CT scans. This dataset was analyzed using a Monte Carlo (MC) application developed in-house using the toolkit gate that is capable to take into account patient-specific anatomy and radiotracer distribution at the voxel level. They compared the absorbed doses obtained with GATE to those calculated with two commercially available software: OLINDA/EXM and STRATOS implementing a dose voxel kernel convolution approach.Absorbed doses calculated with gate were higher than those calculated with OLINDA. The average ratio between gate absorbed doses and OLINDA's was 1.38 ± 0.34 σ (from 0.93 to 2.23). The discrepancy was particularly high for the thyroid, with an average GATE/OLINDA ratio of 1.97 ± 0.83 σ for the six patients. Differences between STRATOS and GATE were found to be higher. The average ratio between GATE and STRATOS absorbed doses was 2.51 ± 1.21 σ (from 1.09 to 6.06).This study demonstrates how the choice of the absorbed dose calculation algorithm may introduce a bias when gamma radiations are of importance, as is the case in nuclear medicine diagnostics.

Published
2015

42. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?

Author

Bardiès M and Irene Buvat

Subjects
Tomography, Emission-Computed, Single-Photon, Carcinoma, Hepatocellular, Radiotherapy, Lymphoma, Non-Hodgkin, Radiotherapy Planning, Computer-Assisted, Liver Neoplasms, Radioimmunotherapy, Iodine Radioisotopes, 3-Iodobenzylguanidine, Neuroendocrine Tumors, Bone Marrow, Neoplasms, Humans, Thyroid Neoplasms, Nuclear Medicine, Radiopharmaceuticals, Tomography, X-Ray Computed
Published
2011

43. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting

Author

Lassmann M, Chiesa C, Flux G, Bardiès M and EANM Dosimetry Committee.

Abstract

Many recent publications in nuclear medicine contain data on dosimetric findings for existing and new diagnostic and therapeutic agents. In many of these articles, however, a description of the methodology applied for dosimetry is lacking or important details are omitted. The intention of the EANM Dosimetry Committee is to guide the reader through a series of suggestions for reporting dosimetric approaches. The authors are aware of the large amount of data required to report the way a given clinical dosimetry procedure was implemented. Another aim of this guidance document is to provide comprehensive information for preparing and submitting publications and reports containing data on internal dosimetry. This guidance document also contains a checklist which could be useful for reviewers of manuscripts submitted to scientific journals or for grant applications. In addition, this document could be used to decide which data are useful for a documentation of dosimetry results in individual patient records. This may be of importance when the approval of a new radiopharmaceutical by official bodies such as EMA or FDA is envisaged.

Published
2010

44. Simulating radial dose of ion tracks in liquid water simulated with Geant4-DNA: a comparative study

Author

Incerti, S, Psaltaki, M, Gillet, P, Barberet, P H, Bardiès, M, Bernal, M A, Bordage, M C, Breton, V, Davidkova, M, Delage, E, El Bitar, Z, Francis, Z, Guatelli, Susanna, Ivanchenko, A, Ivanchenko, V, Karamitros, M, Lee, S B, Maigne, L, Meylan, S, Murakami, K, Nieminen, P, Payno, H, Perrot, Y, Petrovic, I, Pham, Q, Ristic-Fira, A, Santin, G, Sasaki, Takashi, Seznec, H, Shin, J I, Stepan, V, Tran, H N, Villagrasa, C, Incerti, S, Psaltaki, M, Gillet, P, Barberet, P H, Bardiès, M, Bernal, M A, Bordage, M C, Breton, V, Davidkova, M, Delage, E, El Bitar, Z, Francis, Z, Guatelli, Susanna, Ivanchenko, A, Ivanchenko, V, Karamitros, M, Lee, S B, Maigne, L, Meylan, S, Murakami, K, Nieminen, P, Payno, H, Perrot, Y, Petrovic, I, Pham, Q, Ristic-Fira, A, Santin, G, Sasaki, Takashi, Seznec, H, Shin, J I, Stepan, V, Tran, H N, and Villagrasa, C

Abstract

An accurate modeling of radial energy deposition around ion tracks is a key requirement of radiation transport software used for simulations in radiobiology at the sub-cellular scale. The work presented in this paper is part of the on-going benchmarking of the "Geant4-DNA" physics processes and models, which are available in the Geant4 Monte Carlo simulation toolkit for the low energy transport of particles in liquid water. We present for the first time radial dose distributions of incident ion tracks simulated with "Geant4-DNA". Simulation results are compared to other results available in the literature, obtained from analytical calculations, step-by-step Monte Carlo simulations and measurements. They show a reasonable agreement with reference data.

Published
2014

48. Optimization of GATE simulations for whole-body planar scintigraphic acquisitions using the XCAT male phantom with 177Lu-DOTATATE biokinetics in a Siemens Symbia T2.

Author

Costa, G.C.A., Bonifácio, D.A.B., Sarrut, D., Cajgfinger, T., and Bardiès, M.

Abstract

Simulations of planar whole body acquisitions in therapeutic procedures are often extensively time-consuming and therefore rarely used. However, optimising tools and variance reduction techniques can be employed to overcome this problem. In this paper, a variety of features available in GATE are explored and their capabilities to reduce simulation time are evaluated. For this purpose, the male XCAT phantom was used as a virtual patient with 177 Lu-DOTATATE pharmacokinetic for whole body planar acquisition simulations in a Siemens Symbia T2 model. Activity distribution was divided into 8 compartments that were simulated separately. GATE optimization techniques included reducing the amount of time spent in both voxel and detector tracking. Some acceleration techniques led to a decrease of CPU-time by a factor of 167, while image statistics were kept constant. In that context, the simulation of therapeutic procedure imaging would still require 46 days on a single CPU, but this could be reduced to hours on a dedicated cluster. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

50. Hybrid MicroPET Imaging for Dosimetric Applications in Mice: Improvement of Activity Quantification in Dynamic MicroPET Imaging for Accelerated Dosimetry Applied to 6-[18 F]Fluoro-l-DOPA and 2-[18 F]Fluoro-l-Tyrosine

Author

Bretin, F., primary, Mauxion, T., additional, Warnock, G., additional, Bahri, M. A., additional, Libert, L., additional, Lemaire, C., additional, Luxen, A., additional, Bardiès, M., additional, Seret, A., additional, and Plenevaux, A., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results